Drug Profile
Research programme : narrow spectrum kinase inhibitors - TopiVert Pharma
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator TopiVert
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ulcerative colitis
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Ulcerative colitis in United Kingdom (unspecified route)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Ulcerative-colitis in United Kingdom
- 09 May 2016 Preclinical trials in Ulcerative colitis in United Kingdom (unspecified route) before May 2016